Janux Therapeutics (JANX) Other financing activities (2020 - 2026)

Janux Therapeutics (JANX) has reported Other financing activities for 6 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 293.45% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $7.7 million (up 85.67% YoY), while the FY2021 annual figure was $204.2 million, changed N/A from the prior year.
• Other financing activities rose to $3.5 million in Q1 2026 per JANX's latest filing, from $901000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $3.5 million in Q1 2026 and bottomed at $901000.0 in Q1 2025.
• Historically, Other financing activities has averaged $1.9 million across 4 years, with a median of $1.6 million in 2023.
• Annual changes were most pronounced in 2025 — Other financing activities slumped 45.62% — and 2026, when it jumped 293.45%.
• Janux Therapeutics' Other financing activities stood at $1.6 million in 2023, then rose by 4.87% to $1.7 million in 2024, then plunged by 45.62% to $901000.0 in 2025, then surged by 293.45% to $3.5 million in 2026.
• Business Quant data shows JANX's Other financing activities at $3.5 million in Q1 2026, $901000.0 in Q1 2025, and $1.7 million in Q1 2024.